Wealth Management: Investment Views
An interview with Pfizer
One of the greatest breakthroughs during the COVID-19 pandemic has been the development of vaccines. US pharma giant Pfizer and German biotechnology company BioNTech were the first to have their vaccine authorized for emergency use in the West. Since the start of vaccination programmes at the end of 2020, many countries across the developed world are seeing considerable traction in those citizens who have received at least one dose of a COVID-19 vaccine. Leading this race is the Pfizer/ BioNTech vaccine (see figure 1). In the following interview with Pfizer, we find out more about the world’s first mass-produced mRNA vaccine.
An interview with Roche
Besides vaccinations, one component in the fight against COVID-19 is the widespread testing of citizens. In respect to diagnostics, Roche is a long-standing position in our portfolios and one of the leading pharmaceutical companies in the world. In summer 2020, we were fortunate to interview Roche (Investment views: A response to COVID-19) on its initial response to COVID-19. With the advent of the vaccine and rapid advances in testing, we bring you an update on how the world of diagnostics is responding to the fight against COVID-19.